Arvinas (NASDAQ:ARVN – Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.10, Zacks reports. The company had revenue of $0.50 million for the quarter, compared to analyst estimates of $12.39 million. Arvinas had a return on equity of 1.91% and a net margin of 2.94%. Arvinas’s quarterly revenue was down 98.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.48) EPS.
Here are the key takeaways from Arvinas’ conference call:
- ARV-393 is expected to deliver initial monotherapy data at ASH in December, focused on T-cell lymphoma, with additional B-cell lymphoma, durability, and glofitamab-combination data planned for mid-2027. Management said early responses have been observed across lymphoma subtypes and views the program as potentially competitive, though most initial patients were treated below predicted efficacious exposure levels.
- The company plans to dose SBMA patients with the oral ARV-027 androgen-receptor degrader in the first half of 2027, following healthy-volunteer data. Management is targeting approximately 50% reduction in polyQ-AR, which it believes could translate into improved muscle strength and endurance based on preclinical findings.
- ARV-6723, Arvinas’ oral HPK1 degrader, has entered a Phase I monotherapy trial, with pembrolizumab combination dosing planned for the first half of 2027 and initial clinical data expected in the second half of 2027. The company highlighted preclinical activity in checkpoint-resistant models and complete tumor regressions in combination studies, but clinical validation remains pending.
- Development of the LRRK2 degrader ARV-102 remains constrained by an ongoing FDA clinical hold in the U.S.; the company now expects to initiate a Phase Ib PSP trial in Europe and the U.K. in 2027 and may add U.S. sites later. While biomarker and oculomotor findings strengthened management’s confidence, the relationship between these measures and meaningful clinical benefit is not yet established.
- Arvinas ended the quarter with $558.9 million in cash, restricted cash, and marketable securities and projects funding into the second half of 2028. Lower year-over-year R&D and G&A spending supports the runway, although the balance declined from $685.4 million at year-end 2025 and some programs may extend beyond current cash guidance.
Arvinas Trading Down 5.7%
NASDAQ ARVN opened at $7.09 on Wednesday. The stock has a market cap of $457.45 million, a PE ratio of 70.91 and a beta of 1.81. Arvinas has a 12 month low of $6.74 and a 12 month high of $14.51. The company’s 50-day moving average price is $8.02 and its 200-day moving average price is $9.65.
Arvinas News Summary
Here are the key news stories impacting Arvinas this week:
- Positive Sentiment: Arvinas began dosing patients in a Phase 1/2 study of ARV-6723, an oral immuno-oncology drug, and reiterated plans to report clinical data from three early-stage programs in late 2026 and 2027. The company also reported encouraging oculomotor and biomarker changes with ARV-102 in a Phase 1 Parkinson’s disease study. Arvinas Q3 results and corporate update
- Negative Sentiment: Third-quarter revenue was just $0.5 million, far below the $16.93 million consensus estimate and down 98.8% year over year. Arvinas reported a loss of $0.82 per share: better than MarketBeat’s $0.88-loss estimate, but slightly worse than the $0.80-loss estimate cited by Zacks. The loss also widened from $0.48 per share a year earlier. Zacks Q3 earnings report
- Negative Sentiment: HC Wainwright cut its price target to $13 from $18, signaling a more cautious valuation view, though it maintained a Buy rating and its new target remains above the current share price. HC Wainwright analyst rating
Analysts Set New Price Targets
Several equities research analysts have recently issued reports on the stock. Wedbush raised their target price on shares of Arvinas from $11.00 to $12.00 and gave the stock a “neutral” rating in a report on Wednesday, August 5th. BTIG Research reiterated a “buy” rating and set a $18.00 price target on shares of Arvinas in a report on Tuesday, August 4th. Morgan Stanley set a $10.00 price objective on shares of Arvinas in a research report on Monday, August 10th. Wells Fargo & Company downgraded shares of Arvinas from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $15.00 to $11.00 in a research note on Tuesday, August 4th. Finally, HC Wainwright dropped their target price on Arvinas from $18.00 to $13.00 and set a “buy” rating for the company in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $15.18.
Get Our Latest Stock Analysis on ARVN
About Arvinas
Arvinas, Inc is a clinical-stage biopharmaceutical company focused on developing medicines based on targeted protein degradation. The company’s proprietary PROTAC® protein degrader platform is designed to direct the body’s natural cellular machinery to selectively break down disease-causing proteins that may be difficult to address with conventional drug approaches.
Arvinas has concentrated its research and development efforts primarily on oncology, including hormone-driven cancers. Its pipeline has included vepdegestrant, an estrogen receptor protein degrader being developed for patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, as well as other investigational degraders targeting cancer-related proteins.
Read More
- Five stocks we like better than Arvinas
- Can Oil’s Big Rally Deliver Reliable Income? 3 Energy Plays to Watch
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.
